HCW Biologics has developed second-generation, multi-specific T-cell engagers targeting solid tumors, particularly pancreatic cancer, using its proprietary TRBC platform. These T-cell engagers target tissue factor and mesothelin, proven solid tumor antigens, and simultaneously reduce immunosuppression in the tumor microenvironment. Preclinical studies showed promising results, with 100% survival in treated mice compared to zero survival in untreated mice.
This advancement is crucial because pancreatic cancer remains a challenging disease with limited treatment options. Current T-cell engagers are approved for a small number of indications, and HCW Biologics’ approach could significantly expand their applicability to difficult-to-treat solid tumors, potentially revolutionizing treatment paradigms. By addressing the immunosuppressive environment often hindering effective T-cell infiltration, these novel engagers offer a new strategy for enhancing anti-tumor activity.
The TRBC platform allows for the construction of T-cell engagers that not only target cancer antigens and activate T-cells but also mitigate immunosuppression. The lead candidates have demonstrated potent and antigen-specific activity against pancreatic cancer •in vitro• and in humanized mouse models at well-tolerated doses. These findings were presented at the Phoenix Best Science Series hosted by HonorHealth Research Institute.
This development positions HCW Biologics at the forefront of T-cell engager technology. The promising preclinical data suggest the potential for improved outcomes for patients with pancreatic cancer and other solid tumors. The TRBC platform’s versatility may also lead to the development of additional immunotherapies for various diseases, representing a significant advancement in the field of oncology and beyond.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
